$MRNA · OPTIONS PERFORMANCE
Moderna, Inc.Earnings & option results
← All results
Moderna, Inc. options
EXPLORE COMPANY RESEARCH
Moderna: the full stock picture
Earnings history, financials, price action and peer comparisons — all below.EXPLORE THE COMPANY
Moderna (MRNA)
Explore earnings, price action, financials and industry comparisons.
- Symbol
- MRNA
- Sector
- Healthcare
- Industry
- Biotechnology
- Instrument type
- EQUITY
Profile information from our saved company catalog. This is not a live quote or confirmation of current listing status.
EARNINGS & COMPANY RESEARCH
View in calendar ↗MRNA earnings, valuation & price action
NEXT EXPECTED REPORTNov 6 2026Before open · ET
EPS ESTIMATE-1.10
REVENUE ESTIMATE890.25M
Expected dates may change. Estimates use the source’s reporting currency. Quotes and research are snapshots, not live prices.
COMPANY RESEARCH · Healthcare
Moderna, Inc. MRNA
Biotechnology · Updated 11/5/2026
Adjusted closing price · USD241.46 Nov 5
Price50-day average200-day average+916.7% in view
VALUATION & EXPECTATIONS
Trailing P/EN/A
Forward P/EN/A
Trailing P/S40.9×
Forward P/S43.4×
EPS beat rate100%
Revenue beat rate75%
Positive window50%
EPS beats: 8 of 8 comparable reports. Positive price windows: 4 of 8.
Market caps may be up to 14 days old; prices up to seven days old; ratios and analyst estimates up to fourteen days old. Forward multiples use consensus for the fiscal year ending 2026-12-31, not the next 12 months. Negative or unavailable earnings multiples show “N/A”. Forward ADR multiples are omitted when the currency/share basis is not reconciled.
50-day average189.62
200-day average90.46
RSI (14)60
20-day range197.00 – 258.38
Relative volume0.6×
1-year change+916.7%
| Report date | EPS estimate | EPS actual | Surprise | Result | Revenue actual | Price window* | 5 sessions* |
|---|---|---|---|---|---|---|---|
| Jul 31 2026 | -2.03 | -1.97 | +3.0% | Beat | 145M | -4.8% | +2.2% |
| May 1 2026 | -4.45 | -3.40 | +23.6% | Beat | 389M | +3.0% | +18.3% |
| Feb 13 2026 | -2.54 | -2.11 | +16.9% | Beat | 678M | +9.5% | +25.4% |
| Nov 6 2025 | -1.87 | -0.51 | +72.7% | Beat | 1.02B | +4.2% | +5.9% |
| Aug 1 2025 | -2.99 | -2.13 | +28.8% | Beat | 142M | -6.5% | -11.6% |
| May 1 2025 | -2.92 | -2.52 | +13.7% | Beat | 107M | -3.3% | -14.6% |
| Feb 14 2025 | -2.68 | -2.50 | +6.7% | Beat | 956M | +12.0% | +6.2% |
| Nov 7 2024 | -1.91 | 0.03 | +101.6% | Beat | 1.86B | -9.6% | -23.2% |
*Adjusted close before the report date to the first (or fifth) trading close after it. This window can span two sessions and is not an isolated earnings-day return. Figures may be revised by the provider.
Smart Money activity
Recent insider and politician transactions, and disclosed fund positions for MRNA.
Get Pro to see what insiders are doing ahead of earnings.
Explore insider trades, fund holdings and politician activity with an active Pro membership.
Checking membership…
MRNA earnings previews and market catalysts
October 27, 2026 premarket: Celestica jumps, Xylem lowers outlook
2026-10-27 · Celestica climbed on a $40 billion revenue outlook for 2027, while Xylem cut its profit forecast. Royal Caribbean raised guidance as investors awaited the Federal Reserve decision.
October 26, 2026 premarket recap: FICO and Moderna slide as travel stocks rise
2026-10-26 · Ross rose after a UBS upgrade; FICO slid after a Wells Fargo downgrade. Moderna’s cancer-trial reaction and EQT’s signed Range deal round out the key news before open on October 26.
Moderna financials
Revenue, earnings, cash flow and financial strength in one view.
Reporting currency unconfirmed.
Revenue
Net income
Gross profit
Operating income
EBITDA
Operating cash flow
Capital expenditure
Cash
Total assets
Total liabilities
Shareholder equity
Total debt
Net profit margin
Gross margin
Short interest: days to cover
How to read these financial metrics
Figures use the app’s saved statements for the displayed period, not a trailing-year total. Margins divide profit by revenue; quick ratio uses current assets less inventory divided by current liabilities. Compare dates and currencies before comparing companies.
Moderna event catalysts
Company earnings and scheduled market events that may change expectations.
2026-11-06
MRNA earnings
Watch reported results, management’s outlook and the share-price reaction.
See earnings expectations ↑Jobs report · payrolls & unemployment
Read revisions and wages alongside the headline. Strong hiring can support demand but also lift rate expectations.
Release schedule ↗ScheduledConsumer sentiment · preliminary
Watch changes in inflation expectations as well as sentiment.
Release schedule ↗ScheduledCPI inflation
Compare headline and core inflation with expectations; watch Treasury yields and growth stocks.
Release schedule ↗ScheduledMSCI · index review announcement
Review official additions, deletions and weight changes; release time is not specified here.
Release schedule ↗ScheduledInitial jobless claims
Use the multiweek trend to distinguish normal volatility from a sustained increase in layoffs.
Release schedule ↗ScheduledPPI inflation
Watch the surprise versus expectations and implications for margins and interest rates.
Release schedule ↗ScheduledRussell · preliminary additions/deletions
Check the official lists. Preliminary changes can be revised.
Release schedule ↗Scheduled13F filing deadline · Q3 holdings
Filings may arrive earlier and positions can have changed. A filing is not a new trade or a guarantee of buying pressure.
Release schedule ↗ScheduledDates use U.S. Eastern time and can change. Calendar events provide context; they do not determine the direction of a stock move.
Compare MRNA with its peers
Biotechnology · Compare valuation, financial strength and price performance.
Companies with valuation data7
Peer median positive P/E17.5×
MRNA P/E
| Company | Price | Market cap | P/E | Forward P/E | P/S | Forward P/S |
|---|---|---|---|---|---|---|
| MRNAModerna2026-11-05 · USD | 241.46 | 91.2B | 40.9× | 43.4× | ||
| ARCTArcturus Therapeutics Holdings Inc.2026-11-05 · USD | 9.36 | 266.04M | 10.7× | 14.9× | ||
| BNTXBioNTech SE2026-10-20 · USD | 91.17 | 22.9B | 7.7× | |||
| GSKGSK plc2026-11-04 · USD | 51.12 | 103.61B | 17.5× | 2.3× | ||
| INOInovio Pharmaceuticals, Inc.2026-11-05 · USD | 1.45 | 99.84M | 149.8× | |||
| NVAXNovavax, Inc.2026-11-05 · USD | 9.78 | 1.61B | 3.9× | 4.3× | ||
| OGENOragenics, Inc.2026-11-05 · USD | 0.35 | 1.57M |
GSK17.5×
The peer median excludes the selected stock and is based on 1 available positive multiples. P/E median excludes negative or missing earnings multiples. Peer reports can have different fiscal periods and currencies; values are not currency-converted.
Explore MRNA alongside its peers
Biotechnology · 45 companies · Cached market data
Comparison
Compare companies
Tap a bubble to inspect a company, then × to hide it. Undo restores the last company hidden. Bubble area reflects market cap, with a minimum size for visibility.
MRNAModerna, Inc.
Market cap: 91.2B
Price / sales: 40.9×
10 of 45 companies have both plotted values.
P/S distribution
Trailing price-to-sales multiples · 10 companies
Median P/S9.2×
Middle 50%5.1× to 18.7×
MRNA P/S40.9×
2.9×20.6×
Tap a bar to see the companies in that P/S range. MRNA has a higher P/S than 80% of this group.
35 companies excluded from P/S statistics because sales are non-positive or the saved multiple is missing. Statistics include all valid positive values, including those outside the focused chart range.
Companies
Showing 8 of 45 matching companies · Largest market cap first
- Market cap 139.16BP/E 35.1×P/S 10.7×Forward P/E Forward P/S Price snapshot: 2026-11-05↗
- Market cap 91.2BP/E P/S 40.9×Forward P/E Forward P/S Price snapshot: 2026-11-05↗
- Market cap 78.17BP/E P/S Forward P/E Forward P/S Catalog snapshot↗
- Market cap 51.98BP/E P/S Forward P/E Forward P/S Catalog snapshot↗
- Market cap 25.34BP/E P/S Forward P/E Forward P/S Catalog snapshot↗
- Market cap 24.07BP/E P/S Forward P/E Forward P/S Catalog snapshot↗
- Market cap 24.01BP/E P/S Forward P/E Forward P/S Catalog snapshot↗
- Market cap 22.9BP/E P/S 7.7×Forward P/E Forward P/S Price snapshot: 2026-10-20↗
Explore industries
Open an industry for its comparison, valuation and companies.
- Biotechnology45 companies · Median P/E 35.1×P/E based on 3 saved positive multiples
- Advertising Agencies7 companies · Median P/E 13.4×P/E based on 2 saved positive multiples
- Aerospace & Defense28 companies · Median P/E 22.6×P/E based on 8 saved positive multiples
- Agricultural Inputs2 companies
- Airlines8 companies
- Apparel Manufacturing2 companies
- Apparel Retail6 companies · Median P/E 25.7×P/E based on 3 saved positive multiples
- Asset Management14 companies · Median P/E 30.4×P/E based on 4 saved positive multiples
U.S.-listed companies from the app’s catalog. Medians use saved positive P/E values; coverage and snapshot dates vary.
How this comparison works
Uses the saved companies from the same industry and listing market, including MRNA, ordered by cached market cap. Company snapshots can have different dates; the web cache may cover fewer metrics and periods than the app.
Periods end at each company’s dated price snapshot. Change compares the latest saved observation with one at or before the selected period’s start. A daily price change uses consecutive saved sessions. Financial data updates quarterly, so short periods may show no change. Missing history and zero starting values are excluded; a negative starting value uses its absolute value as the denominator.
Metrics use saved ratios and percentages. Market caps use the listing market’s reporting currency; underlying financial statements may use different currencies. Circle sizes have a minimum for touch visibility, and an outlined circle indicates a missing market cap. These comparisons describe data, not recommendations or price predictions.
INDUSTRY COMPARISON
MRNA industry peers
Biotechnology · Oct 16, 2026 · Closing-price performance
Compare MRNA with 1 other stock in the available heatmap coverage.